Precision NanoSystems and Arcturus Therapeutics announce partnership for manufacture of nanomedicines

1 minute read
01 January 2015
Client work

On January 9, 2015, Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, announced a partnership for the manufacture of RNA medicines.

Under the terms of the agreement, Precision’s proprietary NanoAssemblr™ platform will be used to manufacture GMP batches to support clinical studies and commercial development for RNA medicines developed using Arcturus’ proprietary LUNAR™ RNA Therapeutics platform.

Paul Armitage of Gowlings advised Precision NanoSystems with respect to the negotiation of this partnership.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences, Tech, Intellectual Property Law

Related Insights & Resources

View all insights Related Insights & Resources
pills in blue lighting Articles
27 July 2021 FCA upholds award of compound interest in Cefaclor damages appeal
Articles
16 July 2021 The role of IP management and technology transfer in innovation-driven growth in the GCC region
Businessman holding tablet and pointing at a policies and rules concept. Articles
09 July 2021 Proposed amendments to Canadian Patent Rules introduce "excess" claim fees and limit number of office actions
Download or print PDF